カテゴリー：
（ABC order）
ORTHOREBIRTH has entrusted CBC to exclusively distribute and sell ReBOSSIS in Europe. The sale is supposed to start smoothly after ReBOSSIS obtains CE Marking. CBC is a trading firm which operates its business in multiple fields. For example, CBC handles in chemical resins for industry use, electronic materials, medical products, health-promoting foods and so on.
We, ORTHOREBIRTH, has entrusted Kaigen Pharma to produce ReBOSSIS on our behalf. Kaigen Pharma is a major pharmaceutical maker in Japan which produces & sells barium known as contrasting medium, cold medicines known as brand-name “Kaigen” and others. Our all ReBOSSIS are produced at its factory in Otaru, Hokkaido. At the factory, ReBOSSIS is produced under a highly reliable & severe production and quality control before they are shipped to USA, Japan, Taiwan market respectively.
ORTHOREBIRTH have entrusted Kyocera for the distribution and sales of ReBOSSIS-MK in the field of maxillofacial and plastic surgery in Japan in November 2022. Kyocera provides medical products such as artificial joints and dental implants developed with ceramic and metal material technology and surface treatment technology.
KMTI is a U.S. subsidiary of the Kyocera Group, which manufactures and sells medical devices in the United States. ORTHOREBIRTH entered into a business alliance agreement with KMTI in the fall of 2019 for the exclusive sales of ReBOSSIS andReBOSSIS QDS—now marketed as BIOCERA FIBERS and BIOCERA FIBERS QDS—across the U.S. market.
Kyoto Prefectural University of Medicine and Orthorebirth have been jointly conducting the research on the treatment of osteoporotic vertebral body fractures using ReBOSSIS-J impregnated with PRP (platelet rich plasma). In the future, the technology of this joint research shall be utilized and aimed to develop the application to the treatment of all fractures caused by osteoporosis.
Meiji University and ORTHOREBIRTH have been jointly studying to develop Antibacterial Cottony-Type, Synthetic Bone-Void-Filling Materials. This antibacterial type is to prevent any surgical site (bone or joint) from infected by bacteria or virus at the time of operation. Nagoya Institute of Technology (NIT) and Keio University has also participated in this joint development.
Dr. Kasuga at Nagoya Institute of Technology is the originator of ReBOSSIS. ReBOSSIS is featured with its cottony-shape. Dr. Kasuga made a basic but great research & study to invent this cottony shape. Still now, ORTHOREBIRTH has been working with Dr. Kasuga, trying to create much higher-quality type synthetic bone-void-filling materials, new types of scaffolding materials based on our Microfiber Technology and other innovative medical products. Dr. Kasuga also joins our study to develop Antibacterial Cottony-Type, Synthetic Bone-Void-Filling Materials.
ORTHOREBIRTH have entrusted NAKASHIMA HEALTHFORCE for the distribution and sales of ReBOSSIS-J in the territory of Japan in February 2022. NAKASHIMA HEALTHFORCE develops,manufactures, and sells medical devices such as osteosynthesis materials and spinal fixation devices,mainly for artificial joints.
Nissha is a global enterprise operating in three business domains: industrial materials, devices, and medical technology. Leveraging core technologies such as printing, coating, molding, and metal processing, the company provides products and services that meet the needs of diverse markets. Nissha is our contract-manufacturing partner for cotton-shaped artificial bone.
ORTHOREBIRTH have entrusted SHOFU for the distribution and sales of ReBOSSIS-MS in the field of maxillofacial and plastic surgery in Japan in November 2022. SHOFU develops, manufactures, and sells mainly dental materials and equipment.
